Next Article in Journal
The Role of Diffusion Weighted MR Imaging in the Diagnosis of Tendon Injuries of the Ankle and Foot
Previous Article in Journal
Ferroptosis Involvement in Glioblastoma Treatment
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience

by
Dragoș Traian Marius Marcu
1,
Cristina Andreea Adam
2,*,
Dan-Mihai Dorobanțu
3,4,
Delia Lidia Șalaru
1,2,
Radu Andy Sascău
1,2,
Mircea Ovanez Balasanian
1,2,
Liviu Macovei
1,2,
Cătălina Arsenescu-Georgescu
1 and
Cristian Stătescu
1,2
1
Department of Internal Medicine, University of Medicine and Pharmacy “Grigore T. Popa” Iași, 700115 Iași, Romania
2
Institute of Cardiovascular Diseases “Prof. Dr. George I. M. Georgescu” Iași, 700115 Iași, Romania
3
Children’s Health and Exercise Research Centre (CHERC), University of Exeter, Exeter EX1 2LU, UK
4
Congenital Heart Unit, Bristol Royal Hospital for Children and Heart Institute, Bristol BS2 8BJ, UK
*
Author to whom correspondence should be addressed.
Medicina 2022, 58(2), 320; https://doi.org/10.3390/medicina58020320
Submission received: 15 December 2021 / Revised: 15 February 2022 / Accepted: 17 February 2022 / Published: 20 February 2022
(This article belongs to the Section Cardiology)

Abstract

Background and Objectives: Drug-related bradyarrhythmia is a well-documented major adverse event among beta-blocker users and a potential cause for hospitalization or additional interventions. Whether beta-blocker use is associated with specific bradyarrhythmia presentations, and how this relates to other predisposing factors, is not well known. We aim to evaluate the association between beta-blocker use and the type of atrioventricular (AV) conduction disorder in patients with symptomatic bradycardia. Materials and Methods: We conducted a retrospective cohort study on 596 patients with a primary diagnosis of symptomatic bradyarrhythmia admitted to a single tertiary referral center. Of the cases analyzed, 253 patients were on beta-blocker treatment at presentation and 343 had no bradycardic treatment. We analyzed demographics, clinical and paraclinical parameters in relation to the identified AV conduction disorder. A multivariate regression analysis was performed to explore factors associated with beta-blocker use. Results: Of the 596 patients (mean age 73.9 ± 8.8 years, 49.2% male), 261 (43.8%) had a third-degree AV block, 92 (15.4%) had a second-degree AV block, 128 (21.5%) had slow atrial fibrillation, 93 (15.6%) had sick sinus syndrome and 21 (3.5%) had sinus bradycardia/sinus pauses. Beta-blocker use was associated with the female gender (p < 0.001), emergency admission (p < 0.001), dilated cardiomyopathy (p = 0.003), the lower left ventricular ejection fraction (p = 0.02), mitral stenosis (p = 0.009), chronic kidney disease (p = 0.02), higher potassium levels (p = 0.04) and QRS duration > 120 ms (p = 0.02). Slow atrial fibrillation (OR = 4.2, p < 0.001), sick sinus syndrome (OR = 2.8, p = 0.001) and sinus bradycardia/pauses (OR = 32.9, p < 0.001) were more likely to be associated with beta-blocker use compared to the most common presentation (third-degree AV block), after adjusting for other patient characteristics. Conclusions: Beta-blocker use is more likely to be associated with slow atrial fibrillation, sick sinus syndrome and sinus bradycardia/pauses, compared to a second- or third-degree AV block, after adjusting for other patient factors such as gender, admission type, ECG, comorbidities, cardiac function and lab testing.
Keywords: beta-blocker; conduction disorder; adverse drug reactions; bradyarrhythmia; risk factor beta-blocker; conduction disorder; adverse drug reactions; bradyarrhythmia; risk factor

Share and Cite

MDPI and ACS Style

Marcu, D.T.M.; Adam, C.A.; Dorobanțu, D.-M.; Șalaru, D.L.; Sascău, R.A.; Balasanian, M.O.; Macovei, L.; Arsenescu-Georgescu, C.; Stătescu, C. Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience. Medicina 2022, 58, 320. https://doi.org/10.3390/medicina58020320

AMA Style

Marcu DTM, Adam CA, Dorobanțu D-M, Șalaru DL, Sascău RA, Balasanian MO, Macovei L, Arsenescu-Georgescu C, Stătescu C. Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience. Medicina. 2022; 58(2):320. https://doi.org/10.3390/medicina58020320

Chicago/Turabian Style

Marcu, Dragoș Traian Marius, Cristina Andreea Adam, Dan-Mihai Dorobanțu, Delia Lidia Șalaru, Radu Andy Sascău, Mircea Ovanez Balasanian, Liviu Macovei, Cătălina Arsenescu-Georgescu, and Cristian Stătescu. 2022. "Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience" Medicina 58, no. 2: 320. https://doi.org/10.3390/medicina58020320

APA Style

Marcu, D. T. M., Adam, C. A., Dorobanțu, D.-M., Șalaru, D. L., Sascău, R. A., Balasanian, M. O., Macovei, L., Arsenescu-Georgescu, C., & Stătescu, C. (2022). Beta-Blocker-Related Atrioventricular Conduction Disorders—A Single Tertiary Referral Center Experience. Medicina, 58(2), 320. https://doi.org/10.3390/medicina58020320

Article Metrics

Back to TopTop